Edgewise Therapeutics (EWTX) Total Current Liabilities (2020 - 2026)

Edgewise Therapeutics (EWTX) has 7 years of Total Current Liabilities data on file, last reported at $22.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 6.76% year-over-year to $22.5 million; the trailing twelve-month figure through Mar 2026 stood at $22.5 million (up 6.76% YoY), and the FY2025 full-year result was $27.4 million, up 14.71% from the prior year.
• Total Current Liabilities fell to $22.5 million in Q1 2026, from $27.4 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $27.4 million in Q4 2025 to a low of $9.2 million in Q2 2022.
• A 5-year average of $17.5 million and a median of $16.8 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities surged 106.23% in 2022 and climbed 1.12% in 2023, its largest moves.
• Tracing EWTX's Total Current Liabilities over 5 years: stood at $16.6 million in 2022, then climbed by 1.12% to $16.8 million in 2023, then surged by 42.27% to $23.9 million in 2024, then increased by 14.71% to $27.4 million in 2025, then fell by 17.64% to $22.5 million in 2026.
• Business Quant data shows EWTX's Total Current Liabilities at $22.5 million in Q1 2026, $27.4 million in Q4 2025, and $21.6 million in Q3 2025.